The plaintiff filed a motion for a new trial, arguing that, “At a minimum, the verdict shows confusion and lack of ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

Share on Facebook Share on Twitter President Trump is so busy rewriting the U.S. Government it feels he’s at risk for carpal ...

Share on Facebook Share on Twitter Today the AWESOME is in Brewer, Maine. A woman named Heather shared what she saw the other ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

Johnson & Johnson's stock reversed gains made early Wednesday immediately after earnings were released, after the medical technology and drug company beat estimates for the fourth quarter, but offered ...

Johnson & Johnson's stock (JNJ) rose 1.9% early Wednesday, after the medical tech and drug company posted better-than-expected earnings for the fourth quarter, offsetting mixed guidance. The company ...

J&J’s Spravato nasal spray received a label expansion on Tuesday, now approved as a standalone treatment for major depressive ...